Mild bronchial asthma: a modern treatment concept

Mild bronchial asthma (BA) occurs in 50–75% of patients with this disease. It is characterized by clinical symptoms that are controlled by low doses of inhaled glucocorticoids (IGCS) or anti-leukotriene drugs. Mild BA reduces the quality of life of patients, is accompanied by the development of seve...

Full description

Saved in:
Bibliographic Details
Published inMedicinskij sovet no. 15; pp. 29 - 36
Main Authors Emel’yanov, A. V., Leshenkova, E. V., Sergeyeva, G. R.
Format Journal Article
LanguageEnglish
Russian
Published Remedium Group LLC 08.12.2019
Subjects
budesonide
formoterol
intermittent administration
mild bronchial asthma
Online AccessGet full text

Cover

More Information
Summary:Mild bronchial asthma (BA) occurs in 50–75% of patients with this disease. It is characterized by clinical symptoms that are controlled by low doses of inhaled glucocorticoids (IGCS) or anti-leukotriene drugs. Mild BA reduces the quality of life of patients, is accompanied by the development of severe, in some cases fatal exacerbations, and is characterized by a significant cost of treatment. One of the main problems in the management of patients with this disease is their low adherence to IGCS treatment and the excessive use of short-acting 2-adrenomimetic agents. Several clinical studies have shown that the use of a combination of budesonide/formoterol (Symbicort® Turbuhaler®) in an «as needed» mode reduces the incidence of severe exacerbations of mild BA as well as low doses of budesonide, and is characterized by a lower cumulative dose of this glucocorticoid. The results obtained were the basis for the creation of a new treatment concept, which gives preference to the combination of IGCS / formoterol «as needed» in mild BA as a supporting therapy, and for the management of symptoms of the disease.
ISSN:2079-701X
2658-5790
DOI:10.21518/2079-701X-2019-15-29-36